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Background: In an axillary brachial plexus block (ABPB), where relatively large doses of local anesthetics are 
administered, levobupivacaine is preferred due to a greater margin of safety. However, the efficacy of levobupivacaine 
in ABPB has not been studied much. We performed a prospective, double-blinded study to compare the clinical effect 
of 0.375% levobupivacaine with 0.5% levobupivacaine for ultrasound (US)-guided ABPB with nerve stimulation.
Methods: Forty patients undergoing elective upper limb surgery were randomized into two groups: Group I (0.375% 
levobupivacaine) and Group II (0.5% levobupivacaine). All four main terminal nerves of the brachial plexus were 
blocked separately with 7 ml of levobupivacaine using US guidance with nerve stimulation according to study group. 
A blinded observer recorded the onset time for sensory and motor block, elapsed time to be ready for surgery, 
recovery time for sensory and motor block, quality of anesthesia, patient satisfaction and complications. 
Results: There were no significant differences in the time to find nerve locations, time to perform block and number 
of skin punctures between groups. Insufficient block was reported in one patient of Group I, but no failed block was 
reported in either group. There were no differences in the onset time for sensory and motor block, elapsed time to be 
ready for surgery, patient satisfaction and complications.
Conclusions: 0.375% levobupivacaine produced adequate anesthesia for ABPB using US guidance with nerve 
stimulation, without any clinically significant differences compared to 0.5% levobupivacaine. (Korean J Anesthesiol 
2012; 62: 24-29)
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Introduction
Axillary brachial plexus block (ABPB) is an anesthetic option 
commonly used for surgery of the hand, forearm, and elbow 
[1]. The conventional transarterial technique has potential 
problems such as nerve injury due to needle trauma and intra-
neural injection, as well as cardiovascular and CNS toxicity as a 
result of vascular uptake or accidental intravascular injection.
The use of ultrasound (US) has significantly improved the 
quality of nerve blocks by direct visualization of nerves and 
related anatomical structures, needle trajectory and spread of 
local anesthetics (LAs) during injection [2-7]. In addition, US 
guidance increases success rate, minimizes LAs volume needed 
for effective nerve block, and avoids potential complications 
such as intraneural or intravascular injection [2,4,5].
Bupivacaine, ropivacaine and levobupivacaine are commer-
cially available intermediate-acting LAs. They have some 
differences in risk of cardiovascular and CNS toxicity, but 
they have similar anesthetic and analgesic potency [8,9]. In 
ABPB, in which relatively large doses of LAs are administered, 
ropivacaine and levobupivacaine are preferred due to a greater 
margin of safety. 
There have been some studies on the efficacy of bupivacaine 
and ropivacaine in ABPB [10,11], and studies comparing levo-
bupivacaine with bupivacaine or ropivacaine for neuraxial and 
other peripheral nerve blocks [9,12-14]. However, the efficacy 
of levobupivacaine in ABPB has not been studied much [8,15]. 
Therefore, we designed this study to compare the clinical effect 
of 0.375% levobupivacaine with 0.5% levobupivacaine for ABPB 
using US guidance with nerve stimulation.
Materials and Methods
After obtaining approval from the Institutional Review 
Board and written informed consent, forty American Society of 
Anesthesiologists (ASA) physical status I-II patients scheduled 
for elective upper limb surgery, including forearm, wrist and 
hand procedures, were randomly allocated into two groups : 
Group I (n = 20) received ABPB using 0.375% levobupivacaine 
(Chirocaine
Ⓡ, Abbott Scandinavia AB, Solna, Sweden) and 
Group II (n = 20) received ABPB using 0.5% levobupivacaine. 
Patients with clinically significant coagulopathy, infection at 
the injection site, allergy to LAs, preexisting neuromuscular, 
cardiovascular, psychiatric and hepatic conditions, or age < 18 
years or > 65 years were excluded. There were no significant 
differences in patient characteristics between groups (Table 1).
Patients were premedicated with 1-3 mg of midazolam 
(Midazolam
Ⓡ, Bukwang Pharm, Seoul, Korea) intravenously. 
Standard monitoring, including noninvasive blood pressure, 
heart rate and pulse oximetry, was used throughout the 
procedure. Patients were placed in supine position with the 
operative arm abducted to 120
o and externally rotated with the 
forearm flexed to 90
o. 
Identification of the target nerve was performed using a 
SonoSite M-turbo (SonoSite
Ⓡ, Bothell, WA, USA) with a 5-12 
MHz linear transducer by one of the two investigators. The 
transducer was placed in a vertical orientation at the level of 
the anterior axillary fold, and the transducer was adjusted to 
place the axillary artery in the center of the image. Identification 
of each nerve was done by traceback approach technique. A 
22-gauge, 50-mm short-beveled insulated needle (Stimuplex
Ⓡ, 
B. Braun, Melsungen, Germany) was inserted and advanced 
via in-plane technique so that the needle shaft and tip could 
be visualized. The location of the target nerve was confirmed 
with the aid of a nerve stimulator (Stimuplex
Ⓡ Dig RC, B. 
Braun, Melsungen, Germany) simultaneously. At first, a motor 
response was sought by stimulating with a 0.6 to 0.8 mA current 
intensity and a frequency of 2 Hz. After the proper twitch was 
elicited, stimulating intensity was progressively reduced to 
less than 0.5 mA. Once the proper twitch was maintained 
with a current less than 0.5 mA, 1 ml of LA was injected. After 
this injection stopped the twitch, the location was considered 
adequate, and the remaining 6 ml was injected. All four main 
branches were blocked separately with 7 ml of levobupivacaine 
(a total amount of 28 ml) according to the study group. The 
spread of LAs around the target nerve was evaluated and the 
needle tip position was continuously adjusted during injection 
to optimize the impregnation of nerve structure under real-time 
US guidance.
A blinded observer recorded the time to find nerve locations 
(i.e. the time from US application to localization of individual 
nerves), time to perform block (i.e. time from localization of 
individual nerves to completion of LAs injection) and number 
of skin punctures. 
The degree of sensory block was assessed by pinprick in 
the relevant dermatome of the musculocutaneous nerve 
Table 1. Demographic Data
Group I (n = 20) Group II (n = 20)
Age (yr)
Height (cm)
Weight (kg)
ASA physical status I/II (n)
Operation time (min)
Site of operation (n)
    Hand
    Wrist
    Forearm
36.7 ± 15.2
165.3 ± 10.5
65.4 ± 12.3
13/7
70.3 ± 44.0
11
2
 7
40.7 ± 13.2
170.0 ± 9.0
68.6 ± 13.0
12/8
81.3 ± 50.2
6
6
8
Data are mean ± SD or number of patients.  Group I: axillary brachial 
plexus block using 0.375% levobupivacaine. Group II: axillary 
brachial plexus block using 0.5% levobupivacaine.  There were no 
significant differences between groups for any of these variables.26 www.ekja.org
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(forearm), radial nerve (dorsal 1
st and 2
nd intermetacarpal 
area), median nerve (palmar side of the tip of 3
rd finger), and 
ulnar nerve (palmar side of the tip of the 5
th finger), and was 
graded according to a two-grade scale (0 = no block, 1 = loss of 
pinprick sensation). The degree of motor block was measured 
by assessing the following motor functions: elbow flexion for 
the musculocutaneous nerve; extension/supination of arm 
and finger for the radial nerve; flexion/pronation of wrist and 
2-3
rd finger for the median nerve; 4-5
th finger flexion/thumb 
adduction for the ulnar nerve. The degree of motor block was 
graded according to a three-grade scale (0 = no block, 1 = partial 
block, 2 = complete block). Sensory and motor blocks were 
assessed every 5 minutes after injection for 30 minutes. 
Surgical anesthesia was defined as sensory block grade 1 
and motor block grade 1 or 2 in all four nerves. When a patient 
achieved surgical anesthesia, the patient was assumed to be 
“ready for surgery” . The elapsed time to be ready for surgery was 
recorded.
To compare the time to be “ready for surgery” between the 
two groups, degree of sensory and motor block were assessed 
in all patients for 30 minutes. At 30 minutes, the number of 
patients reaching each grade of block was counted. Patients 
who had achieved surgical anesthesia were transferred to 
the operating room, and those that had not achieved surgical 
anesthesia were monitored until they were ready. If surgical 
anesthesia was not achieved within 1 hour, the block was 
considered as a “failed block” , and conversion to general 
anesthesia was made. 
The quality of anesthesia was measured by need for opioid 
during operation. In case of pain more than 4 on a numerical 
rating scale or uncomfortable sensation developed during 
surgery, 50 μg boluses of fentanyl (Fentanyl
Ⓡ, Myung-moon 
Pharm, Seoul, Korea) were administered intravenously. If pain 
persisted 5 minutes after administration of 50 μg fentanyl, an 
additional 50 μg was given intravenously. If no intraoperative 
analgesia was required, the block was assumed to be a “complete 
block” . When less than 100 μg of fentanyl was needed to 
complete surgery, the block was assumed to be a “sufficient 
block” . If more than 100 μg of fentanyl was needed to complete 
surgery, the block was assumed to be an “insufficient block” . 
If fentanyl supplementation was not sufficient to complete 
surgery, the block was considered a “failed block” , and 
conversion to general anesthesia was made. 
Any complications, such as paresthesia, hematoma, infection 
and LAs toxicity, were noted during block performance, in 
the perioperative period, and during the 24 hours after LAs 
injection.
After the end of surgery, patients were transferred to the 
recovery room and patient satisfaction was assessed using a two 
point scale : “0 = good; if ever operated on again in the future, 
I want the same anesthetic technique” and “1 = bad; if ever 
operated on again in the future, I want a different anesthetic 
technique. ”
24 hours after LAs injection, complete recovery of sensory 
and motor block was checked. 
Statistical analysis was performed using SPSS for Windows, 
version 17.0 (SPSS Inc, Chicago, IL, USA). All data were 
expressed as mean ± SD or absolute numbers. Wilcoxon-Mann-
Whitney test was used to compare the distributions of age, 
height, weight, operation time, time to find nerve locations, 
time to perform block, number of skin punctures, onset time 
for sensory and motor block, and elapse time to be ready for 
surgery. Chi-square test was used to determine if there was a 
relationship between ASA physical status, site of operation, 
need for intraoperative opioid, and patient satisfaction. A P 
value of less than 0.05 was considered statistically significant. 
Results
There were no significant differences in the average time 
to find nerve locations, time to perform block and number 
of skin punctures between groups. There were no significant 
differences in sensory and motor block time to grade 1 between 
groups (Table 2). 
At 30 min after injection of LAs, the percentage of patients 
who reached sensory block grade 2 (complete sensory block) 
in the musculocutaneous, radial, median and ulnar nerve 
dermatomes were 75%, 40%, 15%, 40% in group I, and 80%, 
40%, 30%, 60% in group II (Table 3). The number of patients 
who reached motor block grade 2 (complete motor block) in the 
musculocutaneous, radial, median and ulnar nerve were 70%, 
55%, 10%, 15% in group I, and 75%, 40%, 25%, 20% in group 
II (Table 3). There were no statistically significant differences 
between two groups. The average elapsed time to be ready 
for surgery was 32.5 ± 20.6 minutes and 21.1 ± 12.0 minutes 
respectively, but this was not significantly different (Table 2).
There was no significant difference in the quality of blockade 
between the groups (Table 2). One patient in group I required 
100 μg of IV fentanyl, but no failed block was reported in either 
group. No patient demonstrated any signs of LAs toxicity. 
Patient satisfaction was good in both groups (Table 2).
All patients reported complete recovery of sensory and 
motor function. 
Discussion 
With US-guided ABPB combined with nerve stimulation, 
our study showed that 28 ml of 0.375% or 0.5% levobupivacaine 
for ABPB induced similar clinical efficacy, including the time 
to block onset, elapsed time to be ready for surgery, quality 27 www.ekja.org
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of block as well as the percentage of patients with complete 
sensory block and complete motor block at 30 min after LAs 
injection.
The reasons why we compared the clinical effect of 0.375% 
levobupivacaine to 0.5% levobupivacaine in particular were: 
1) 0.5% levobupivacaine is the drug of choice for regional 
anesthesia in our institute, 2) ABPB with low-dose LAs has 
advantage of reducing risk of LAs toxicity, 3) in order to achieve 
surgical anesthesia, however, the dose of LAs cannot be 
markedly lowered.
Levobupivacaine, the S(-)-enantiomer of bupivacaine, has 
similar anesthetic and/or analgesic potency [8,9,12] in addition 
to less cardiac and central nervous system toxicity [16,17] 
compared to bupivacaine. Its duration of sensory block is longer 
than ropivacaine [8,15], so it has the advantage in providing 
prolonged postoperative pain control. The use of low-dose LAs 
in ABPB, where relatively large volume of LAs are indicated, 
also may reduce the risk of LAs toxicities. There have been 
some efforts to lower the dose of bupivacaine and ropivacaine 
in ABPB [11], but only a few studies with similar investigations 
with levobupivacaine in ABPB. Among many possible 
concentrations, we chose to use 0.375% levobupivacaine based 
on the findings of Cox et al. and Hickey et al. [13,18] as well as 
our experience in regional anesthesia for upper limb surgery. 
Hickey et al. [18] compared 0.25% ropivacaine with 0.25% 
bupivacaine for supraclavicular block and concluded that the 
0.25% concentration for brachial plexus block is not sufficient to 
achieve surgical anesthesia because of a slow onset and a high 
rate of inadequate block. Cox et al. [13] compared 0.25% or 0.5% 
levobupivacaine with 0.5% bupivacaine for supraclavicular 
block and reported that 0.25% levobupivacaine had a slower 
onset as well as a lower overall success rate than 0.5% 
levobupivacaine, although there were no significant differences.
In our study, complete sensory and motor blocks were 
achieved with only 28 ml of LAs in nearly all patients, except 
for one patient in group I who needed 100 μg of IV fentanyl 
intraoperatively. This high success rate seems to be due to 
the combined use of US/nerve stimulation, multiple-nerve 
infiltration and operator’s skill.
Before the introduction of real time ultrasonographic 
guidance in regional anesthesia, block failures were mostly 
due to maldistribution of LAs or multiple septation within 
the axillary brachial plexus sheath [19,20]. These septations 
or fascial compartments serve to limit the spread of injected 
Table 3. Patients with Complete Block in Each Nerve Territory 30 
Minutes after Injection
Location Group I (n = 20) Group II (n = 20)
Complete sensory block
    Musculocutaneous n.
    Radial n.
    Median n.
    Ulnar n.
Complete motor block
    Musculocutaneous n.
    Radial n.
    Median n.
    Ulnar n.
15 (75%)
8 (40%)
3 (15%)
8 (40%)
16 (80%)
11 (55%)
2 (10%)
3 (15%)
18 (90%)
8 (40%)
6 (30%)
12 (60%)
15 (75%)
8 (40%)
5 (25%)
4 (20%)
Data are expressed as number (%). Group I: axillary brachial plexus 
block using 0.375% levobupivacaine, Group II: axillary brachial 
plexus block using 0.5% levobupivacaine. There was no significant 
differences between the groups.
Table 2. Results of Axillary Brachial Plexus Block with Levobupivacaine
Group I (n = 20) Group II (n = 20)
Time to find nerve location (min)
Time to perform block (min)
Skin puncture (n)
Sensory block time to grade 1 (min)
    Musculocutaneous n.
    Radial n.
    Median n.
    Ulnar n.
Motor block time to grade 1 (min)
    Musculocutaneous n.
    Radial n.
    Median n.
    Ulnar n.
Elapsed time to be ready for surgery (min)
Intraoperative opioid : need/need not (n)
Patient satisfaction: G/N
1.6 ± 0.7
6.5 ± 3.1
1.5 ± 0.5
10.5 ± 10.6
15.1 ± 12.8
15.4 ± 12.1
18.0 ± 15.8
7.1 ± 6.9
9.8 ± 8.9
24.0 ± 19.6
25.5 ± 19.3
32.5 ± 20.6
1/19
20/0
2.0 ± 1.1
6.5 ± 2.1
1.5 ± 0.5
6.8 ± 5.5
12.8 ± 10.8
14.3 ± 14.8
11.2 ± 10.3
7.2 ± 5.5
11.6 ± 9.6
16.1 ± 13.6
14.1 ± 12.4
21.1 ± 12.0
0/20
20/0
Data are mean ± SD or number of patients.  Group I: axillary brachial plexus block using 0.375% levobupivacaine.  Group II: axillary brachial 
plexus block using 0.5% levobupivacaine.  Sensory block was graded according to a three grade scale: 0 = no block, 1 = loss of pinprick sensation, 
2 = loss of touch sensation.  Motor block was graded using a three grade scale: 0 = no block, 1 = partial block, 2 = complete block.  There were no 
significant differences between groups for any of these variables. 28 www.ekja.org
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LAs around the brachial plexus nerve. The brachial plexus 
block guided by US was more effective than those guided 
by a nerve stimulator. US guidance for nerve localization 
significantly improved the success rate and quality of block, 
shortened the performance time of peripheral nerve blocks, 
and decreased potential complications such as intraneural 
and intravascular injection [2-7]. These improvements were 
mainly due to increased accuracy of needle positioning and 
direct visualization of diffusion of LAs during injection. Despite 
the advantages of real-time US application, ultrasonography 
alone is not perfect because ultrasonography is indirect, and 
allows for subjective interpretation by the individual operator. 
Therefore, we used a combination of US and nerve stimulation 
to attempt a 100% success rate with only 28 ml of LAs, without 
untoward side effects. US-guided ABPB using nerve stimulation 
decreased the performance time and reduced complications 
compared to nerve stimulation alone [21-23]. 
In this study, multiple-injection technique was used to 
provide more effective anesthesia. Clinical studies have suggested 
that higher block success is achieved with multiple-injection 
technique than with single- or double-injection techniques 
[24,25]. With single-injection technique, success rate of ABPB 
varies from 54% to 80% [26] because the musculocutaneous 
and the radial nerve were insufficiently anesthetized with 
single-injection technique [27]. One explanation could be that 
the locations of the radial and musculocutaneous nerve are 
difficult to find. The ultrasonographic image of the radial nerve 
is covered by the acoustic shadow of the axillary artery. Further, 
the musculocutaneous nerve is separated from the other nerves 
at the level of the axilla and is located between the biceps and 
coracobrachial muscles. Another explanation could be that 
there are multiple septations within the axillary neurovascular 
sheath which interferes the diffusion of LAs [19,20].
In our study, ABPB was performed by either an experienced 
anesthesia staff or one anesthesiology resident experienced in 
US-guided ABPB with at least 20 procedures under supervision 
of the experienced anesthesia staff. Block performance by 
skilled operators may have contributed to the high success rate. 
The percentage of patients who showed complete sensory 
block and complete motor block in each of the four innervation 
areas at 30 minutes after LAs injection was mostly below 
50%, except for the musculocutaneous nerve (70-80%) and 
motor blockage of the radial nerve in group I (55%). Our 
results are consistent with the study of Liisanantti et al. [8]; at 
45 minutes after injection of 45 ml of 0.5% levobupivacaine, 
complete sensory block and complete motor block (30%) was 
less frequent than in the 0.5% ropivacaine (67%) and 0.5% 
bupivacaine (47%) groups. The low rate of complete block may 
be due to the low volume (28 ml) used in our study.
Our mean performance time was within 10 minutes. This 
indi  cates that US-guided ABPB using nerve stimulation was 
not only safe, but also efficacious in busy operating situations 
compared to the simple transarterial technique. Short 
performance time is also closely related to patients’ satisfaction.
In conclusion, when performing ABPB with 0.375% or 0.5% 
levobupivacaine, there were no significant differences in the 
clinical efficacy, including the time to block onset, quality 
of block and patient satisfaction. If we consider the fact that 
clinical doses of LAs can result in systemic toxicity, 0.375% 
levobupivacaine would be a reliable and safer choice for ABPB.
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